Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research.
Lampalizumab delivered intravenously to cynomolgus monkeys elicits nearly 10-fold increases in serum Factor D levels within five hours, effectively neutralizing its inhibitory activity[1].
References:
[1]. Yuan X, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017 Mar;102(3):466-475.
[2]. Hanus J, et al. Current therapeutic developments in atrophic age-related macular degeneration. Br J Ophthalmol. 2016 Jan;100(1):122-7.